NCT02670213 - A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2016

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Congenital Bleeding DisorderCongenital FXIII Deficiency

Interventions

DRUG

recombinant factor XIII

No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.

Trial Locations (8)

Nagoya University Hospital_Blood Transfusion, Aichi

Gamagori Hospital, Gamagori-shi, Aichi

Chugoku Central Hospital, Hiroshima

Kure Medical Center and Chugoku Cancer Center, Kure-shi, Hiroshima

Nikko Memorial Hospital, Muroran, Hokkaido,

Saitama Children's Med Centre_Hematology-Oncology, Saitama

Takashima Municipal Hospital, Shiga

Ogikubo Hospital_Pediatries & Blood, Tokyo